M.D，Ph.D，研究員,，碩士生導(dǎo)師,，博士生導(dǎo)師,，博士后合作導(dǎo)師
中山七院副院長,、中山大學(xué)醫(yī)學(xué)院副院長，
中山七院精準(zhǔn)醫(yī)學(xué)中心主任,、基礎(chǔ)醫(yī)學(xué)教研室主任,、科研中心常務(wù)副主任、臨床醫(yī)學(xué)研究大數(shù)據(jù)中心執(zhí)行主任,、廣東省消化系統(tǒng)惡性腫瘤防治研究重點實驗室副主任,；中山大學(xué)醫(yī)學(xué)院病理學(xué)系主任
?
個人簡介：
中山醫(yī)科大學(xué)臨床醫(yī)學(xué)專業(yè)學(xué)士，美國路易斯安那州立大學(xué)醫(yī)學(xué)中心細(xì)胞生物學(xué)博士,、康奈爾大學(xué)醫(yī)學(xué)院博士后,、美國醫(yī)學(xué)遺傳學(xué)學(xué)院臨床Fellow。曾就職于康奈爾大學(xué)醫(yī)學(xué)院附屬醫(yī)院病理科6年,，從事基因檢測、診斷的臨床工作,。有中美兩國的臨床實踐及醫(yī)學(xué)研究工作經(jīng)歷近30年,，在解讀與疾病和健康相關(guān)的遺傳學(xué)因素方面有豐富的臨床經(jīng)驗。作為一名資深精準(zhǔn)醫(yī)學(xué)領(lǐng)域的科學(xué)家,，潘逸航博士帶領(lǐng)其課題組團隊致力于疾病精準(zhǔn)診療多學(xué)科交叉研究,。近五年，在Advanced Materials,、Gut,、Signal Transduction and Targeted Therapy、Biomaterials,、Drug Resistance Updates,、Advanced?Science、British Journal of Cancer,、BMC Medicine等國際期刊發(fā)表通訊作者論文40來篇,，申請國內(nèi)外專利十余項，參與撰寫指南兩件,，擔(dān)任多個SCI雜志審稿人,，主持或參與10余項國家級等科研項目，包含主持兩項國家重點研發(fā)計劃課題,、一項國自然面上項目,、一項省重點研發(fā)項目（Co-PI）。擔(dān)任中國醫(yī)院協(xié)會精準(zhǔn)醫(yī)療分會等多個學(xué)會副主任委員,。
?
研究領(lǐng)域：
(1).?納米醫(yī)學(xué)
針對腫瘤治療脫靶,、療效差,、耐藥等問題，主要開展以新型金屬基納米材料為生物活性藥物的構(gòu)建與抗腫瘤應(yīng)用,。
近期代表性研究成果：
（1）?Yuzhi Xu#, Si-Yang Liu#, Leli Zeng*, Hansu Ma, Yanfei Zhang, Huihui Yang, Yuchen Liu, Shuo Fang, Jing Zhao, Yunsheng Xu, Charles R. Ashby Jr, Yulong He*, Zong Dai*, Yihang Pan*. An Enzyme-Engineered Nonporous Copper(I) Coordination Polymer Nanoplatform for Cuproptosis-based Synergistic Cancer Therapy. Advanced Materials, 2022 Sep, 34(43):e2204733.
（2）?Jia Li#, Leli Zeng#*, Zheng Wang, Hengxing Chen, Shuo Fang, Jinquan Wang, Chao-Yun Cai, Enming Xing, Xinxing Liao, Zhi-Wei Li, Charles R. Ashby Jr, Zhe-Sheng Chen*, Hui Chao*, Yihang Pan*. Cycloruthenated Self-Assembly with Metabolic Inhibition to Efficiently Overcome Multidrug Resistance in Cancers. Advanced Materials, 2022 Jan, 34(1), e2100245.
（3）?Guochuang Chen#, Leli Zeng#, Bo Bi, Xiuyu Huang, Miaojuan Qiu, Ping Chen, Zhi-Ying Chen, Yulong He, Yihang Pan*, Yu Chen*, Jing Zhao*. Engineering Bifunctional Calcium Alendronate Gene-Delivery Nanoneedle for Synergistic Chemo/Immuno-Therapy Against HER2 Positive Ovarian Cancer. Advanced Science, 2023 March 18, 10(14):2204654.
（4）?Tao Feng, Zixin Tang, Johannes Karges, Jinchao Shen, Chengzhi Jin, Yu Chen, Yihang Pan*, Yulong He*, Liangnian Ji, Hui Chao*, Exosome camouflaged coordination-assembled Iridium(III) photosensitizers for apoptosis-autophagy-ferroptosis induced combination therapy against melanoma. Biomaterials, 2023 Jun 24, 301:122212.
（5）?Jing Zhao, Xiuyu Huang, Peng Liu, Miaojuan Qiu, Binbin Li, Yingfei Wen, Yongshu Li, Qiang Wang, Meiying Wu*, Yu Chen*, Yihang Pan*. Engineering Alendronate-Composed Iron Nanochelator for Efficient Peritoneal Carcinomatosis Treatment. Advanced Science, 2022 Sep, 9(30):e2203031.
?
(2).?分子醫(yī)學(xué)
針對腫瘤發(fā)生發(fā)展,，尤其腫瘤耐藥等問題，主要開展新靶點挖掘與基因線路機制探索,。
近期代表性研究成果：
（1）?Zi-Ning Lei#, Qiu-Xu Teng#, Qin Tian#, Wei Chen#, Yuhao Xie, Kaiming Wu, Qianlin Zeng, Leli Zeng*, Yihang Pan*, Zhe-Sheng Chen*, Yulong He*. Signaling pathways and therapeutic interventions in gastric cancer. Signal Transduction and Targeted Therapy, 2022 Oct, 7(1):358.
（2）?Jinxiang Wang#, Leli Zeng#, Nisha Wu, Yanling Liang, Jie Jin, Mingming Fan, Xiaoju Lai, Zhe-Sheng Chen, Yihang Pan*, Fangyin Zeng*, Fan Deng*, Inhibition of Phosphoglycerate dehydrogenase induces ferroptosis and overcomes enzalutamide resistance in castration-resistant prostate cancer cells. Drug Resistance Updates, 2023 Sep, 70:100985.
（3）?Hailin Zou#, Juan Luo#, Yibo Guo, Liang Deng, Leli Zeng, Yihang Pan*, Peng Li*,?Tyrosine phosphorylation-mediated YAP1-TFAP2A interactions coordinate transcription and trastuzumab resistance in HER2+ breast cancer. Drug Resistance Updates, 2024 Mar, 73:?101051.
（4）?Juan Luo#, Hailin Zou#, Yibo Guo, Tongyu Tong, Yun Chen, Yunjun Xiao, Yihang Pan*, Peng Li*, The oncogenic roles and clinical implications of YAP/TAZ in breast cancer, British Journal of Cancer, 2023 Feb, 128(9):1611-1624.
（5）?Zi-Ning Lei, Qin Tian, Qiu-Xu Teng, John N.D. Wurpel, Leli Zeng*, Yihang Pan*, Zhe-Sheng Chen*. Understanding and targeting resistance mechanisms in cancer. MedComm, 2023 May, 4(3): e265.
?
?
(3).?臨床醫(yī)學(xué)大數(shù)據(jù)
針對消化道疾病,、腫瘤等疾病的發(fā)生及預(yù)后，進行多影響因素的大型隊列數(shù)據(jù)分析,。
近期代表性研究成果：
（1）?Qiangsheng He, Chongfei Huang, Xiwen Qin, Yuanyuan Yu, Di Tang, Junjie Huang, Zi Chong Kuo, Yuyao Ling, Deli Mao, Bin Xia, Wenjing Li, Kuiqing Lu, Man Yang, Yulong He, Wenbo Meng*, Jinqiu Yuan*, Yihang Pan*, Confounded association between proton pump inhibitor use and risk of biliary tract cancer: Result from three cohorts, International Journal of Cancer, 2023 May, 153(5): 942-949.
（2）?Man Yang#, Qiangsheng He#, Fang Gao, Krish Nirantharakumar, Tonny Veenith, Xiwen Qin, Amy T Page, Martin C S Wong, Junjie Huang, Zi Chong Kuo, Bin Xia, Changhua Zhang, Yulong He, Wenbo Meng*, Jinqiu Yuan*, Yihang Pan*. Regular use of proton-pump inhibitors and risk of stroke: a population-based cohort study and meta-analysis of randomized-controlled trials. BMC Medicine, 2021 Dec, 19(1), 316.12.
（3）?Qiangsheng He#, Man Yang, Xiwen Qin, Die Fan, Jinqiu Yuan*, Yihang Pan*. Risk stratification for proton pump inhibitor-associated type 2 diabetes: a population-based cohort study. Gut, 2021 Nov, 70(11), 2212-2213.
（4）?Qiangsheng He#, Bin Xia#, Wenbo Meng#, Die Fan, Zi-Chong Kuo, Junjie Huang, Xiwen Qin, Huachun Zou, Yulong He, Changhua Zhang, Shuo Fang, Yihang Pan*, Man Yang*, Jinqiu Yuan*. No Associations Between Regular Use of Proton Pump Inhibitors and Risk of All-Cause and Cause-Specific Mortality: A Population-Based Cohort of 0.44 Million Participants. American Journal of Gastroenterology, 2021 Nov, 116(11), 2286-2291.
（5）?Jinqiu Yuan#, Yanhong Jessika Hu, Jie Zheng, Jean Hee Kim, Tim Sumerlin, Youpeng Chen, Yulong He, Changhua Zhang, Jinling Tang, Yihang Pan*, Michael Moore*. Long-term use of antibiotics and risk of type 2 diabetes in women: a prospective cohort study. International Journal of Epidemiology, 2020 Oct, 49(5), 1572-1581.
?
研究生招生和博后招聘
1）?研究生招生：中山七院（學(xué)科：基礎(chǔ)醫(yī)學(xué)）,，中山大學(xué)醫(yī)學(xué)院（學(xué)科：生物與醫(yī)藥），兩邊均可招生,；
2）?博士后招聘（不限方向,，長期招聘，深圳待遇,，中大質(zhì)量,，歡迎隨時咨詢）
3）?科研助理招聘：醫(yī)學(xué)、生物學(xué)等相關(guān)學(xué)科背景專業(yè)者優(yōu)先,。
課題組經(jīng)費充足,，氛圍融洽，具有從副研究員,、助理研究員,、博士后到博士生、碩士生的人才培養(yǎng)與成長的完整體系,，能為不同層次和不同學(xué)科背景的優(yōu)秀學(xué)子提供優(yōu)越的求學(xué)與成才平臺,。
?
聯(lián)系方式